Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Cumberland Pharmaceuticals (CPIX) over the last 17 years, with Sep 2025 value amounting to $65.9 million.

  • Cumberland Pharmaceuticals' Liabilities and Shareholders Equity fell 14.14% to $65.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $279.3 million, marking a year-over-year decrease of 12.31%. This contributed to the annual value of $75.6 million for FY2024, which is 7.57% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Liabilities and Shareholders Equity stood at $65.9 million for Q3 2025, which was down 2.96% from $67.9 million recorded in Q2 2025.
  • Over the past 5 years, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity peaked at $96.7 million during Q1 2022, and registered a low of $65.9 million during Q3 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $78.5 million (2024), whereas its average is $78.6 million.
  • As far as peak fluctuations go, Cumberland Pharmaceuticals' Liabilities and Shareholders Equity rose by 10.02% in 2022, and later declined by 14.20% in 2025.
  • Cumberland Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $84.5 million in 2021, then climbed by 10.02% to $92.9 million in 2022, then dropped by 12.00% to $81.8 million in 2023, then decreased by 7.57% to $75.6 million in 2024, then decreased by 14.14% to $65.9 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $65.9 million for Q3 2025, versus $67.9 million for Q2 2025 and $69.9 million for Q1 2025.